Publications

2018

MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.

Yohe, M. E., et. al.

M7824, a novel bifunctional anti-PD-L1/TGFbeta Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.

Knudson, K. M., et. al.

Synthesis and Biological Evaluation of Fluorescent Bryostatin Analogues.

Cummins, T. J., et. al.

2017

Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.

Simmons, J. K., et. al.

2016

Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.

Noonan, A. M., et al.

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Holkova, B., et al.

RCC1-dependent activation of Ran accelerates cell cycle and DNA repair, inhibiting DNA damage-induced cell senescence.

Cekan, P., et al.

Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression.

Felsenstein, K. M., et al.

Genomic profiling of multiple sequentially acquired tumor metastatic sites from an “exceptional responder” lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.

Biswas, R., et. al.

Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin.

Xin, H. W., et. al.

Biological activity of the bryostatin analog Merle 23 on mouse epidermal cells and mouse skin.

Kelsey, J. S., et. al.

Quantitation of TGF-beta proteins in mouse tissues shows reciprocal changes in TGF-beta1 and TGF-beta3 in normal vs neoplastic mammary epithelium.

Flanders, K. C., et. al.

Cell autonomous or systemic EGFR blockade alters the immune-environment in squamous cell carcinomas.

Mascia, F., et. al.